Pimozide in the treatment of newly admitted schizophrenic patients

Psychopharmacology

Volumn 76, Issue 1, 1982, Pages 13-19

  Chouinard, G ^a,b   Annable, L ^a  

^a Allan Memorial Institute   (Canada)

^b CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Chlorpromazine; Neuroleptics; Parkinsonism; Pimozide; Schizophrenia; Supersensitivity; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; PIMOZIDE; PLACEBO; PROCYCLIDINE;

ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED STUDY; DRUG THERAPY; HUMAN; MAJOR CLINICAL STUDY; PARKINSONISM; SCHIZOPHRENIA; SEX DIFFERENCE; TARDIVE DYSKINESIA; THERAPY;

ACUTE DISEASE; ADULT; CHLORPROMAZINE; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMAN; MALE; MIDDLE AGE; PARKINSON DISEASE, SECONDARY; PIMOZIDE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0020043938     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF00430747     Document Type: Article

References (30)

1. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
2. Clozapine: a unique new neuroleptic
3. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity
4. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia
5. Pimozide in the treatment of chronic schizophrenic patients
6. Ethopropazine and benztropine in neuroleptic-induced parkinsonism
7. Tardive dyskinesia and antiparkinsonian medication
8. Extrapyramidal symptom rating scale
9. Pimozide in chronic schizophrenic outpatients
10. Evidence that pimozide is not a partial agonist of dopamine receptors
11. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia
12. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia
13. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment
14. Depot injections and tardive dyskinesia
15. Drug and sociotherapy in the aftercare of schizophrenic patients
16. Neuroleptic-induced changes of tyrosine hydroxylase activity in rat striatum in vitro and in vivo
17. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug
18. Effect of cholinergic and anticholinergic agents on tardive dyskinesia
19. Phenothiazine treatment in acute schizophrenia
20. The brief psychiatric rating scale
21. Pimozide: a review of its pharmacological properties and therepeutic uses in psychiatry
22. High dose pimozide in the treatment of acutely agitated schizophrenia
23. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release
24. High-dose pimozide in acutely ill, newly admitted schizophrenic inpatients
25. A homologous radioimmunoassay for human prolactin
26. Criteria for subtyping schizophrenia
27. Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors
28. Neuroleptics and brain self-stimulation behavior